logo-loader

Destiny Pharma to push ahead with next-generation antibiotic after $15mln IPO

Published: 04:17 29 Sep 2017 EDT

Destiny Pharma plc (LON:DEST), only the second biotech float this year, is bringing through a next-generation antibiotic.

Chief executive Neil Clark tells Proactive The bulk of the £15mln they raised will go towards funding a phase IIb clinical trial on XF-73 for the prevention of post-surgical staphylococcus aureus infections, including the deadly MRSA.

Destiny Pharma's nasal spray project already delivering "more than hoped for"

Destiny Pharma PLC (AIM:DEST, OTC:DTTYF) CEO Neil Clark speaks to Proactive after releasing fresh data from the update from a research collaboration into a novel biotherapeutic treatment for COVID-19 and influenza. Clark says that the project has already delivered "more than hoped for" and...

on 05/02/2023